Benjamin Idemudia Akhiwu1, Helen Oluwadamilola Akhiwu2, Tolulope Afolaranmi3, Nyam Chuwang4, Ambrose Elugbe5, Acheng Shedrach6, Pam Luka7, Patricia Odumosu8, Patrick Oladele Olorunfemi9, Samuel Agida Adoga10, Olugbenga Silas11, Benjamin Tagbo Ugwu12, Akinola Ladeinde13, Godwin Eremwan Imade14, Atiene Solomon Sagay14. 1. Oral and Maxillofacial Surgery Department, University of Jos, Jos University Teaching Hospital, Lamingo Permanent Site, Jos, Plateau State, Nigeria. 2. Department of Pediatrics, Jos University Teaching Hospital, Lamingo Permanent Site, Jos, Plateau State, Nigeria. 3. Department of Community Medicine, University of Jos, Jos University Teaching Hospital, Jos, Plateau State, Nigeria. 4. STAMINA Genomics Laboratory, Department of Human Anatomy, Faculty of Basic Medical sciences, University of Jos, Jos, Plateau State, Nigeria. 5. Department of Dental and Maxillofacial Surgery, Jos University Teaching Hospital, Jos, Plateau State, Nigeria. 6. Genomics and Postgraduate Research Laboratory, College of Health Sciences, University of Jos, Jos, Plateau State, Nigeria. 7. Biotechnology Center, National Veterinary Research Institute, Vom, Jos, Plateau State, Nigeria. 8. Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Jos, Jos, Plateau State, Nigeria. 9. Department of Pharm, Microbiology and Biotechnology, University of Jos, Jos, Plateau State, Nigeria. 10. Department of Ear, Nose and Throat surgery, University of Jos, Jos University Teaching Hospital, Lamingo Permanent Site, Jos, Plateau State, Nigeria. 11. Department of Pathology, University of Jos, Jos University Teaching Hospital, Lamingo Permanent Site, Jos, Plateau State, Nigeria. 12. Department of Surgery, University of Jos, Jos University Teaching Hospital, Lamingo Permanent Site, Jos, Plateau State, Nigeria. 13. Oral and Maxillofacial Surgery Department, College of Medicine, University of Lagos, Lagos State, Nigeria. 14. Department of OBGYN, Faculty of Clinical Sciences, College of Health Sciences, University of Jos, Jos, Plateau State, Nigeria.
Abstract
INTRODUCTION: head and neck cancers have essentially been a disease of the elderly but recent studies are beginning to demonstrate their increasing incidence in young people with infections such as human papilloma virus (HPV). This study was carried out to determine the prevalence of high risk Human papilloma virus (hrHPV) related oropharyngeal carcinoma and its prevalent genotypes as well as their strength of association with HIV in adult Nigerian subjects. METHODS: this was a cross-sectional study of 41 patients with oropharyngeal carcinomas seen over a 2-year period. Patients had incisional and/or excisional biopsy done under anesthesia. A portion of the specimen from which the DNA was extracted was placed in Digene HC2 DNA collection device while the 2nd portion for histopathological analysis was fixed using 10% Neutral Buffered Formalin (NBF) and embedded in paraffin blocks. Oropharyngeal cancer HPV genotyping was done using HPV genotypes 14 real-tm quant kit (SACACE, Italy). The data was analyzed using SPSS version 23. RESULTS: prevalence of HPV was 17.1% with a male to female ratio of 2.7: 1. The identified genotypes were 16, 33, 35 and 52 with 28.6% of patients having more than one genotype. Most of the age groups studied were affected. Squamous cell carcinoma and ameloblastic carcinoma were the cancers associated with HPV. HPV was not identified in the HIV positive patients. CONCLUSION: high-risk human papilloma virus genotypes 16, 33, 35 and 52 are associated with oropharyngeal carcinoma in Nigeria but were not found in HIV patients. This finding provides a strong evidence for the use of the 9-valent prophylactic vaccine for the prevention of oropharyngeal cancer in Nigeria. Public awareness and HPV prevention strategies should reduce significantly the incidence of oropharyngeal carcinomas in our environment. Copyright: Benjamin Idemudia Akhiwu et al.
INTRODUCTION: head and neck cancers have essentially been a disease of the elderly but recent studies are beginning to demonstrate their increasing incidence in young people with infections such as human papilloma virus (HPV). This study was carried out to determine the prevalence of high risk Human papilloma virus (hrHPV) related oropharyngeal carcinoma and its prevalent genotypes as well as their strength of association with HIV in adult Nigerian subjects. METHODS: this was a cross-sectional study of 41 patients with oropharyngeal carcinomas seen over a 2-year period. Patients had incisional and/or excisional biopsy done under anesthesia. A portion of the specimen from which the DNA was extracted was placed in Digene HC2 DNA collection device while the 2nd portion for histopathological analysis was fixed using 10% Neutral Buffered Formalin (NBF) and embedded in paraffin blocks. Oropharyngeal cancer HPV genotyping was done using HPV genotypes 14 real-tm quant kit (SACACE, Italy). The data was analyzed using SPSS version 23. RESULTS: prevalence of HPV was 17.1% with a male to female ratio of 2.7: 1. The identified genotypes were 16, 33, 35 and 52 with 28.6% of patients having more than one genotype. Most of the age groups studied were affected. Squamous cell carcinoma and ameloblastic carcinoma were the cancers associated with HPV. HPV was not identified in the HIV positive patients. CONCLUSION: high-risk human papilloma virus genotypes 16, 33, 35 and 52 are associated with oropharyngeal carcinoma in Nigeria but were not found in HIV patients. This finding provides a strong evidence for the use of the 9-valent prophylactic vaccine for the prevention of oropharyngeal cancer in Nigeria. Public awareness and HPV prevention strategies should reduce significantly the incidence of oropharyngeal carcinomas in our environment. Copyright: Benjamin Idemudia Akhiwu et al.
Entities:
Keywords:
Human papilloma virus; Nigeria; oropharyngeal carcinoma
Authors: H S van Monsjou; M L F van Velthuysen; M W M van den Brekel; E S Jordanova; C J M Melief; A J M Balm Journal: Int J Cancer Date: 2011-08-02 Impact factor: 7.396
Authors: Xavier Castellsagué; Laia Alemany; Miquel Quer; Gordana Halec; Beatriz Quirós; Sara Tous; Omar Clavero; Llúcia Alòs; Thorsten Biegner; Tomasz Szafarowski; Maria Alejo; Dana Holzinger; Enrique Cadena; Edith Claros; Gillian Hall; Jan Laco; Mario Poljak; Maria Benevolo; Elena Kasamatsu; Hisham Mehanna; Cathy Ndiaye; Núria Guimerà; Belen Lloveras; Xavier León; Juan C Ruiz-Cabezas; Isabel Alvarado-Cabrero; Chang-Suk Kang; Jin-Kyoung Oh; Marcial Garcia-Rojo; Ermina Iljazovic; Oluseyi F Ajayi; Flora Duarte; Ashrafun Nessa; Leopoldo Tinoco; Marco A Duran-Padilla; Edyta C Pirog; Halina Viarheichyk; Hesler Morales; Valérie Costes; Ana Félix; Maria Julieta V Germar; Marisa Mena; Arzu Ruacan; Asha Jain; Ravi Mehrotra; Marc T Goodman; Luis Estuardo Lombardi; Annabelle Ferrera; Sani Malami; Estela I Albanesi; Pablo Dabed; Carla Molina; Rubén López-Revilla; Václav Mandys; Manuel E González; Julio Velasco; Ignacio G Bravo; Wim Quint; Michael Pawlita; Nubia Muñoz; Silvia de Sanjosé; F Xavier Bosch Journal: J Natl Cancer Inst Date: 2016-01-28 Impact factor: 13.506